Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCN052
MIFTS: 42

Secondary Adrenal Insufficiency

Categories: Endocrine diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Secondary Adrenal Insufficiency

About this section

MalaCards integrated aliases for Secondary Adrenal Insufficiency:

Name: Secondary Adrenal Insufficiency 54 74
Hypocortisolism Secondary to Another Disorder 74

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:
Sources

Summaries for Secondary Adrenal Insufficiency

About this section
NIH Rare Diseases : 54 Adrenal insufficiency is an endocrine disorder that occurs when the adrenal glands do not produce enough of certain hormones. Secondary adrenal insufficiency occurs when the pituitary gland (a pea-sized gland at the base of the brain) fails to produce enough adrenocorticotropin (ACTH), a hormone that stimulates the adrenal glands to produce the hormone cortisol. The lack of these hormones in the body can be caused by reduction or cessation of corticosteroid medication, the surgical removal of pituitary tumors, or changes in the pituitary gland. Symptoms of secondary adrenal insufficiency may include severe fatigue, loss of appetite, weight loss, nausea, vomiting, diarrhea, muscle weakness, irritability, and depression. Treatment includes replacing the hormones that the adrenal glands are not making. The dose of each medication is adjusted to meet the needs of each affected individual.

MalaCards based summary : Secondary Adrenal Insufficiency, also known as hypocortisolism secondary to another disorder, is related to turner syndrome and hypopituitarism. An important gene associated with Secondary Adrenal Insufficiency is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and FoxO signaling pathway. The drugs Remifentanil and Sufentanil have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotype is renal/urinary system.

Sources

Related Diseases for Secondary Adrenal Insufficiency

About this section

Diseases in the Acute Adrenal Insufficiency family:

Secondary Adrenal Insufficiency

Diseases related to Secondary Adrenal Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 turner syndrome 29.7 IGF1 IGFBP3
2 hypopituitarism 29.6 IGF1 IGFBP3 INS
3 pituitary gland disease 29.4 AVP IGF1 INS
4 insulin-like growth factor i 29.3 IGF1 IGFBP3 INS
5 hypoadrenocorticism, familial 11.2
6 chromophobe adenoma 10.1 AVP INS
7 diabetes insipidus 10.1 AVP INS
8 pituitary hormone deficiency, combined, 2 10.1 AVP IGF1
9 slipped capital femoral epiphysis 10.1 IGF1 IGFBP3
10 diffuse idiopathic skeletal hyperostosis 10.0 IGF1 IGFBP3
11 marasmus 10.0 IGF1 IGFBP3
12 hypothyroidism 10.0
13 sheehan syndrome 10.0 IGF1 INS
14 mammographic density 10.0 IGF1 IGFBP3
15 donohue syndrome 10.0 IGF1 INS
16 isolated growth hormone deficiency, type ib 10.0 IGF1 IGFBP3
17 growth hormone deficiency 10.0 IGF1 IGFBP3
18 acid-labile subunit deficiency 10.0 IGF1 IGFBP3
19 osteoporosis, juvenile 10.0 IGF1 IGFBP3
20 pituitary adenoma 1, multiple types 10.0 IGF1 IGFBP3
21 laron syndrome 10.0 IGF1 IGFBP3
22 rubeosis iridis 10.0 IGF1 INS
23 endocrine pancreas disease 10.0 IGF1 INS
24 urinary system disease 10.0 AVP INS
25 endocrine organ benign neoplasm 10.0 IGF1 INS
26 anovulation 10.0 IGF1 INS
27 osteogenesis imperfecta, type i 10.0 IGF1 IGFBP3
28 acanthosis nigricans 10.0 IGF1 INS
29 craniopharyngioma 10.0 IGF1 INS
30 exudative vitreoretinopathy 1 10.0 IGF1 IGFBP3
31 colorectal adenoma 10.0 IGF1 IGFBP3
32 cell type benign neoplasm 10.0 IGF1 INS
33 hyperandrogenism 10.0 IGF1 INS
34 nutritional deficiency disease 10.0 IGF1 IGFBP3
35 male reproductive organ cancer 10.0 IGF1 IGFBP3
36 sleep apnea 10.0 IGF1 INS
37 male reproductive system disease 10.0 IGF1 IGFBP3
38 overnutrition 10.0 IGF1 INS
39 microvascular complications of diabetes 5 10.0 IGF1 INS
40 thyrotropin-releasing hormone deficiency 10.0
41 autoimmune hepatitis 10.0
42 brain injury 10.0
43 hepatitis 10.0
44 spinal cord injury 10.0
45 traumatic brain injury 10.0
46 broken heart syndrome 10.0
47 gonadal disease 10.0 IGF1 INS
48 glucose metabolism disease 9.9 IGF1 INS
49 silver-russell syndrome 9.9 IGF1 IGFBP3
50 acquired metabolic disease 9.9 IGF1 INS

Graphical network of the top 20 diseases related to Secondary Adrenal Insufficiency:



Diseases related to Secondary Adrenal Insufficiency
Sources

Symptoms & Phenotypes for Secondary Adrenal Insufficiency

About this section

MGI Mouse Phenotypes related to Secondary Adrenal Insufficiency:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.8 AVP IGF1 INS
Sources

Drugs & Therapeutics for Secondary Adrenal Insufficiency

About this section

Drugs for Secondary Adrenal Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Remifentanil Approved Phase 4 132875-61-7 60815
2
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Etomidate Approved Phase 4,Not Applicable 33125-97-2 667484 36339
5
Cisatracurium Approved Phase 4 96946-41-7
6
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
7
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-23-7 5754
8
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-03-3
9
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-43-4 5816
10
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 329-65-7 838
11
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
12
Fluticasone Approved, Experimental Phase 4,Phase 3 90566-53-3 62924
13
Budesonide Approved Phase 4 51333-22-3 5281004 63006
14
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 2 25122-46-7, 25122-41-2 5311051 32798
15
Desoximetasone Approved Phase 4,Phase 2 382-67-2 5311067
16
Cosyntropin Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 16960-16-0 16129617
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Cortisone Experimental Phase 4 53-06-5 222786
22
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
23 Anesthetics, Intravenous Phase 4,Not Applicable
24 Anesthetics Phase 4,Not Applicable
25 Cholinergic Antagonists Phase 4
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
27 Neuromuscular Nondepolarizing Agents Phase 4
28 Neuromuscular Agents Phase 4
29 Analgesics Phase 4
30 Neuromuscular Blocking Agents Phase 4
31 Analgesics, Opioid Phase 4
32 Adjuvants, Anesthesia Phase 4,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable,Early Phase 1
34 Narcotics Phase 4
35 Hypnotics and Sedatives Phase 4,Not Applicable
36 Central Nervous System Depressants Phase 4,Not Applicable
37 Cholinergic Agents Phase 4
38 Anesthetics, General Phase 4,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
42 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
44 Epinephryl borate Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
45 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
46 Hydrocortisone hemisuccinate Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
47 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
48 Sympathomimetics Phase 4,Phase 3,Not Applicable,Early Phase 1
49 Adrenergic alpha-Agonists Phase 4,Phase 3,Not Applicable,Early Phase 1
50 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients Unknown status NCT02111265 Phase 4 Remifentanil;Cisatracurium;Sufentanil
2 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
3 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) Completed NCT01546922 Phase 4 Hydrocortisone
4 Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma Completed NCT00238927 Phase 4 inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)
5 Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01186653 Phase 4 budesonide / formoterol;fluticasone/salmeterol
6 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
7 Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers Completed NCT01194700 Phase 4 Seretide 250(8puffs) via Evohaler actuator;Seretide 250 (8 puffs)/placebo via Volumatic spacer;Seretide 250/placebo 8 puffs via Aerochamber Plus spacer;Seretide 250/placebo via Synchro-Breathe
8 Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% Recruiting NCT03212963 Phase 4 Halobetasol Topical Lotion
9 Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis Recruiting NCT02340169 Phase 4 Topicort® (desoximetasone) Topical Spray, 0.25%
10 Dose of Corticosteroids in COPD Recruiting NCT01742338 Phase 4 Low Dose Corticosteroids;High Dose Corticosteroids
11 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
12 Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers Withdrawn NCT03752190 Phase 4 Cosyntropin
13 COrticosteroid in Congenital Adrenal Hyperplasia Unknown status NCT02552251 Phase 2, Phase 3
14 Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency Completed NCT00575341 Phase 3 Dehydroepiandrosterone;placebo
15 Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Completed NCT00060398 Phase 3 dexamethasone
16 Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02729051 Phase 3 FF/UMEC/VI;FF/VI;UMEC;Placebo;Albuterol/salbutamol
17 DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis Recruiting NCT02527421 Phase 3 DFD01 Spray
18 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Active, not recruiting NCT01603407 Phase 3 Prednisone;Prednisone;Deflazacort
19 Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD) Unknown status NCT01373008 Phase 2 Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
20 Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis Completed NCT01232543 Phase 2 Product 0405
21 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Completed NCT02601469 Phase 2 DSXS
22 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression. Completed NCT02932891 Phase 2 DSXS topical
23 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Completed NCT02932878 Phase 2 DSXS topical
24 Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS Completed NCT02933528 Phase 2 DSXS Topical product
25 Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression Completed NCT01698333 Phase 2 122-0551
26 An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris Completed NCT02720627 Phase 2 cortexolone 17α-propionate
27 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis Completed NCT02595008 Phase 2 DSXS
28 HPA Axis Study in Japanese Adults Completed NCT01407510 Phase 2 Mapracorat
29 HPA Axis Study in Adults Completed NCT01408511 Phase 2 Mapracorat
30 An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris Completed NCT01831960 Phase 2 cortexolone 17α-propionate
31 Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product Completed NCT02933502 Phase 2 DSXS topical product
32 Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study Completed NCT01043393 Phase 2 Desoximetasone 0.25% spray
33 DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis Completed NCT02131324 Phase 2 DFD06 Cream;Clobetasol Propionate Cream 0.05%
34 Dexamethasone to Treat Oral Lichen Planus Completed NCT00111072 Phase 2 dexamethasone 0.01% solution
35 Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis Completed NCT01166646 Phase 2 Halobetasol Proprionate Lotion 0.05%;Halobetasol Proprionate Cream 0.05%
36 Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris Completed NCT01600222 Phase 2 LEO 90100
37 Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Completed NCT00004990 Phase 2 Dexamethasone
38 An Open-Label Study to Assess Safety Recruiting NCT03645499 Phase 2 Topical TA-102 A;Topical TA-102 B;Topical TA-102 C
39 Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 Recruiting NCT03179605 Phase 2 DFD06
40 A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects Recruiting NCT03819218 Phase 2 MC2-01 cream
41 NeSST2: The Development of a Noninvasive Short Synacthen Test Suspended NCT03514589 Phase 2 nasal Tetracosactide;IV tetracosactide
42 Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis Terminated NCT03245385 Phase 2 Treatment with Halobetasol propionate 0.05% topical spray
43 Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis Withdrawn NCT03298581 Phase 2 Halobetasol Propionate
44 Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers Completed NCT00936793 Phase 1 Darunavir;Ritonavir;Beclomethasone Dipropionate HFA
45 Metabolic and Endocrine Effects of Repeated Epidural and Sacroiliac Joint Corticosteroid Injections Unknown status NCT01717430
46 Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency Unknown status NCT03000231
47 The PIT-TBI Pilot Study Unknown status NCT02480985 Not Applicable
48 Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy Completed NCT01209507
49 Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome Completed NCT02368379 Not Applicable
50 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate Completed NCT00575029 Not Applicable megestrol acetate

Search NIH Clinical Center for Secondary Adrenal Insufficiency

Sources

Genetic Tests for Secondary Adrenal Insufficiency

About this section
Sources

Anatomical Context for Secondary Adrenal Insufficiency

About this section

MalaCards organs/tissues related to Secondary Adrenal Insufficiency:

42
Pituitary, Brain, Testes, Adrenal Gland, Thyroid, Endothelial, Kidney
Sources

Publications for Secondary Adrenal Insufficiency

About this section

Articles related to Secondary Adrenal Insufficiency:

(show top 50) (show all 111)
# Title Authors Year
1
Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma. ( 30449786 )
2019
2
A case of severe rhabdomyolysis associated with secondary adrenal insufficiency and autoimmune hepatitis. ( 30898957 )
2019
3
Small Cell Lung Cancer with Pituitary Metastasis Presenting as Secondary Adrenal Insufficiency: A Case Report and Literature Review. ( 30772889 )
2019
4
Continuous subcutaneous hydrocortisone infusion in a woman with secondary adrenal insufficiency. ( 30353412 )
2019
5
Long-acting intramuscular ACTH stimulation test for the diagnosis of secondary adrenal insufficiency in children. ( 30530907 )
2019
6
Secondary adrenal insufficiency from steroid use and co-prescribing of cytochrome p450 3A4 inhibitors. ( 30924569 )
2019
7
Hyponatremia Due to Secondary Adrenal Insufficiency. ( 30935186 )
2019
8
Secondary Adrenal Insufficiency due to Intra-articular Glucocorticoid Injections. ( 30954999 )
2019
9
Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis. ( 30386198 )
2018
10
Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. ( 28750490 )
2018
11
Evaluation of the frequency of adrenal crises and preventive measures in patients with primary and secondary adrenal insufficiency in Switzerland. ( 29376554 )
2018
12
Secondary adrenal insufficiency in pregnancy: any differences? ( 29546743 )
2018
13
Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role? ( 30123187 )
2018
14
Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. ( 30324794 )
2018
15
Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality. ( 29174931 )
2017
16
Pituitary Antibodies in an Adolescent with Secondary Adrenal Insufficiency and Turner Syndrome. ( 27355580 )
2017
17
National German Audit of Diagnosis, Treatment, and Teaching in Secondary Adrenal Insufficiency. ( 28351092 )
2017
18
Gastric cancer with pituitary metastasis presenting as symptomatic secondary adrenal insufficiency: A case report. ( 28421712 )
2017
19
Primary Hypothyroid and Secondary Adrenal Insufficiency-Searching the Missing Link. ( 28571201 )
2017
20
Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial. ( 28686664 )
2017
21
Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma. ( 28871578 )
2017
22
Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. ( 28945828 )
2017
23
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate: Case report. ( 29062559 )
2017
24
Characterization of Cortisol Secretion Rate in Secondary Adrenal Insufficiency. ( 29264545 )
2017
25
A Case of Psychosis in a Patient with Secondary Adrenal Insufficiency: A Possible Etiological Role of a Hypocortisolemic-induced Increase in Proinflammatory Cytokines. ( 29344425 )
2017
26
A case of stiff-person syndrome due to secondary adrenal insufficiency. ( 28552871 )
2017
27
Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. ( 26928716 )
2016
28
A Case of Primary and Secondary Adrenal Insufficiency in Children. ( 26092585 )
2016
29
Recovery of Adrenal Function in Patients with Glucocorticoids Induced Secondary Adrenal Insufficiency. ( 26676337 )
2016
30
Reversible Cardiomyopathy Accompanied by Secondary Adrenal Insufficiency. ( 26920218 )
2016
31
"Petrified Ears" in Secondary Adrenal Insufficiency. ( 27042511 )
2016
32
Esophageal eosinophilia in secondary adrenal insufficiency. ( 27186162 )
2016
33
Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like? ( 27211575 )
2016
34
Mifepristone Accelerates HPA Axis Recovery in Secondary Adrenal Insufficiency. ( 27516913 )
2016
35
Large-Dose Glucocorticoid Induced Secondary Adrenal Insufficiency in Spinal Cord Injury. ( 28119833 )
2016
36
Takotsubo cardiomyopathy in a patient with pituitary adenoma and secondary adrenal insufficiency. ( 26816449 )
2015
37
Primary vs secondary adrenal insufficiency: ACTH-stimulated aldosterone diagnostic cut-off values by tandem mass spectrometry. ( 25620457 )
2015
38
Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. ( 25656494 )
2015
39
Secondary adrenal insufficiency: an overlooked cause of hyponatremia. ( 25699130 )
2015
40
The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency--results from a randomized controlled trial. ( 25705800 )
2015
41
Opioid-induced secondary adrenal insufficiency presenting as hypercalcaemia. ( 26161260 )
2015
42
Concomitant giant cell arteritis and secondary adrenal insufficiency. ( 26169623 )
2015
43
Hyponatremia due to Secondary Adrenal Insufficiency Successfully Treated by Dexamethasone with Sodium Chloride. ( 26319655 )
2015
44
Acute psychosis in the course of treatment of acute adrenal crisis with hydrocortisone in the patient with secondary adrenal insufficiency - a case study. ( 26488344 )
2015
45
Phosphoglucomutase-1 deficiency: Intrafamilial clinical variability and common secondary adrenal insufficiency. ( 26768186 )
2015
46
Flexion contractures of the legs as the manifestation of secondary adrenal insufficiency due to Sheehan's syndrome. ( 22996815 )
2014
47
Iatrogenic Cushing syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: a case report and review. ( 23778239 )
2014
48
Acute secondary adrenal insufficiency as the presenting manifestation of small-cell lung carcinoma. ( 24532238 )
2014
49
Secondary adrenal insufficiency after glucocorticosteroid administration in acute spinal cord injury: a case report. ( 24969098 )
2014
50
Health-related quality of life in primary and secondary adrenal insufficiency. ( 25252879 )
2014
Sources

Variations for Secondary Adrenal Insufficiency

About this section
Sources

Expression for Secondary Adrenal Insufficiency

About this section
Search GEO for disease gene expression data for Secondary Adrenal Insufficiency.
Sources

Pathways for Secondary Adrenal Insufficiency

About this section

Pathways related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 12.35 IGF1 IGFBP3 INS
2
FoxO signaling pathway 38
Show member pathways
 11.63 IGF1 INS
3
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.6 IGF1 INS
4
Adipogenesis 1
11.58 IGF1 INS
5
HIF-1 signaling pathway 38
11.43 IGF1 INS
6
Cardiac Progenitor Differentiation 1
11.09 IGF1 INS
7
Ovarian steroidogenesis 38
11.01 IGF1 INS
8
Differentiation Pathway 1
10.94 IGF1 INS
9
Senescence and Autophagy in Cancer 1
10.82 IGF1 IGFBP3 INS
10
Aldosterone-regulated sodium reabsorption 38
10.72 IGF1 INS
11
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 67
10.28 IGF1 IGFBP3
Sources

GO Terms for Secondary Adrenal Insufficiency

About this section

Cellular components related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 AVP IGF1 IGFBP3 INS
2 extracellular region GO:0005576 9.55 AVP IGF1 IGFBP3 INS PGM1
3 insulin-like growth factor ternary complex GO:0042567 8.96 IGF1 IGFBP3
4 insulin-like growth factor binding protein complex GO:0016942 8.62 IGF1 IGFBP3

Biological processes related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.72 AVP IGF1 INS
2 regulation of signaling receptor activity GO:0010469 9.69 AVP IGF1 INS
3 positive regulation of gene expression GO:0010628 9.67 AVP IGF1 INS
4 positive regulation of cell growth GO:0030307 9.56 AVP INS
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.54 IGF1 INS
6 cellular protein metabolic process GO:0044267 9.54 IGF1 IGFBP3 INS
7 glucose metabolic process GO:0006006 9.52 INS PGM1
8 activation of protein kinase B activity GO:0032148 9.48 IGF1 INS
9 positive regulation of glucose import GO:0046326 9.46 IGF1 INS
10 ERK1 and ERK2 cascade GO:0070371 9.43 AVP IGF1
11 positive regulation of mitotic nuclear division GO:0045840 9.4 IGF1 INS
12 positive regulation of glycolytic process GO:0045821 9.32 IGF1 INS
13 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.26 AVP IGF1
14 positive regulation of glycogen biosynthetic process GO:0045725 9.16 IGF1 INS
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 8.96 IGF1 IGFBP3
16 positive regulation of MAPK cascade GO:0043410 8.8 IGF1 IGFBP3 INS

Molecular functions related to Secondary Adrenal Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.16 IGF1 INS
2 insulin-like growth factor receptor binding GO:0005159 8.96 IGF1 INS
3 hormone activity GO:0005179 8.8 AVP IGF1 INS
Sources

Sources for Secondary Adrenal Insufficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....